Tagamet
(Cimetidine)Phase 3Small molecule
Tagamet is one of 145 small molecule programs targeting HIV infection. It is currently in Phase 3.
6
Indications
18
Total Trials
1
Active Trials
144
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tagamet
DDT MedTech, LLC
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Interaction2 trials
HIV infection1 trial
AIN1 trial
Peptic ulcer1 trial
10 more indications
Pneumonia1 trial
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02555852·4,238,504 enrolled
Intravenous1 trial
Breast Cancer1 trial
TED1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
TAGAMET
NDA NDA017939
Jan 1, 1982
TAGAMET
NDA NDA017924
Jan 1, 1982
TAGAMET
NDA NDA017920
Oct 31, 1985
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
NDA NDA019434
Jun 19, 1995
TAGAMET HB
NDA NDA020238
Jul 9, 1999
TAGAMET HB 200
NDA NDA020951
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cimetidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDT MedTech, LLC